Saghmos Therapeutics’ Post

Saghmos Therapeutics reposted this

We are excited to announce a Notice of Allowance from the Japanese Patent Office for a patent for our Phase 3-ready product, ST-62516 (trimetazidine), a cardiorenal metabolic modulator. The patent will provide exclusivity through 2037, with broad claims for the reduction of acute kidney injury in patients with chronic kidney disease (CKD) undergoing procedures with contrast dyes. https://lnkd.in/egWKrZBK

Saghmos Therapeutics Announces Receipt of Notice of Allowance from Japanese Patent Office for Phase 3-Ready Cardiorenal Metabolic Modulator ST-62516

Saghmos Therapeutics Announces Receipt of Notice of Allowance from Japanese Patent Office for Phase 3-Ready Cardiorenal Metabolic Modulator ST-62516

businesswire.com

Wonderful news, Anna and team.

Paula Norbom

⚙️Health Technology Talent Advisory Expert (Biotech, Pharmaceutical, Digital Health & Medical Device) 🚀Executive Search | Recruiting | Contract Professionals | 🔗Founder & Moderator Serious Talent®️ Chats

6mo

Just reading this now, Anna. Congratulations on your Notice of Allowance from the Japanese Patent Office!

Curtis Bramley

Financial Advisor at Baystate Financial

7mo

Congratulations Anna, that’s terrific! We should reconnect

Don Alexander, CPC

💊 𝐄𝐦𝐩𝐨𝐰𝐞𝐫𝐢𝐧𝐠 𝐭𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜 𝐚𝐧𝐝 𝐬𝐜𝐢𝐞𝐧𝐭𝐢𝐟𝐢𝐜 𝐭𝐨𝐨𝐥𝐬 𝐩𝐫𝐨𝐝𝐮𝐜𝐭 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐨𝐫𝐬 by placing execs who drive successful outcomes. 💊

7mo

Awesome!

Resa Schlossberg

Partner and Head of Intellectual Property and Technology Transactions at Skadden, Arps, Slate, Meagher & Flom LLP & Affiliates

7mo

Congratulations, Anna!

Elena Petrossian

Senior Director, Financial Controller at Carisma Therapeutics

7mo

Congratulations, Anna!

Larisa Yedigarova, MD, PhD

Healthcare Executive - Medical Affairs, Clinical Development

7mo

Congratulations, Anna! Big win!

See more comments

To view or add a comment, sign in

Explore topics